Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barbara Ann Karmanos Cancer Institute
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Suitable related donor as determined by the treating physician
High resolution molecular HLA typing is mandatory for HLA Class I and II
Diagnosis of hematological malignancy
Patients with one of the following hematologic malignancies, and felt to be transplant candidates by their treating physician are eligible to enroll on this protocol:
Non-Hodgkin lymphoma, any complete remission (CR)/partial remission (PR)
Hodgkin disease, any CR/PR/stable disease (SD)
Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) any CR; for non-CR AML or ALL, bone marrow blast \< 20% within 4 weeks of transplant and peripheral blood (PB) absolute blast count \< 500/μl on the day of initiation of conditioning
Myelodysplastic syndrome (MDS), treated or untreated
Chronic myelogenous leukemia (CML) in chronic phase or accelerated phase
Chronic myelomonocytic leukemia (CMML)
Multiple myeloma, any CR/PR/SD
Chronic lymphocytic leukemia (CLL) any CR/PR
Myelofibrosis and other myeloproliferative disorders; bone marrow blasts less than 20 percent within four weeks of transplant and peripheral blood absolute blast counts less than 500 per microliter on the day of initiation of conditioning
Age \>= 18 and able to cooperate with oral medication intake
Agrees to participate, and informed consent signed
Karnofsky performance status (KPS) \>= 60, Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
Creatinine clearance \> 60 mL/min
Ejection fraction \> 50%
Serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 3 X upper limit of normal
Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) or diffusion capacity of carbon monoxide (DLCO) \> 50% predicted
You may not be if
Bone marrow or Ex vivo engineered or processed graft (cluster of differentiation \[CD\]34+ enrichment, T-cell depletion, etc)
Patients with documented uncontrolled central nervous system (CNS) disease
Active donor or recipient serology positive for human immunodeficiency virus (HIV)
Known contraindication to administration of Tacrolimus or Thymoglobulin
Active Hepatitis B or C
Patients with coronary heart disease (recent myocardial infarctions, angina, cardiac stent, or bypass surgery in the last 6 months) need to be cleared with a stress echocardiogram or nuclear myocardial perfusion stress test, and cardiology consult; all other cardiac history will be at the discretion of the Principal Investigator
